



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

**Grant Number:** 2R01AI070042-11 REVISED  
**FAIN:** R01AI070042

**Principal Investigator(s):**  
Alan N. Engelman, PHD

**Project Title:** Integrase Structural Virology

Byron, Elayn  
Senior Director, Research Administration  
450 Brookline Avenue  
Boston, MA 022155450

**Award e-mailed to:** grantsandcontracts@dfci.harvard.edu

**Period Of Performance:**

**Budget Period:** 04/01/2016 – 03/31/2017

**Project Period:** 04/01/2006 – 03/31/2021

Dear Business Official:

The National Institutes of Health hereby revises this award to reflect a decrease in the amount of \$37,500 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to DANA-FARBER CANCER INST in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI070042. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Julie M. Bergerud  
Grants Management Officer  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

---

**SECTION I – AWARD DATA – 2R01AI070042-11 REVISED****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$142,269
Fringe Benefits	\$42,007
Materials & Supplies	\$31,068
Travel	\$3,938
Other	\$18,447
Subawards/Consortium/Contractual Costs	\$117,150

Federal Direct Costs	\$354,879
Federal F&A Costs	\$178,297
Approved Budget	\$533,176
Total Amount of Federal Funds Obligated (Federal Share)	\$533,176
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$533,176</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE)** (\$-37,500)

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
11	\$533,176	\$533,176
12	\$533,176	\$533,176
13	\$533,176	\$533,176
14	\$533,176	\$533,176
15	\$533,176	\$533,176

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

**CFDA Name:** Allergy, Immunology and Transplantation Research  
**CFDA Number:** 93.855  
**EIN:** 1042263040A1  
**Document Number:** RAI070042C  
**PMS Account Type:** P (Subaccount)  
**Fiscal Year:** 2016

IC	CAN	2016	2017	2018	2019	2020
AI	8472325	\$533,176	\$533,176	\$533,176	\$533,176	\$533,176

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** A26I / **OC:** 414B / **Released:** WAUGHJ 03/25/2016  
**Award Processed:** 03/25/2016 07:01:13 PM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 2R01AI070042-11 REVISED**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 2R01AI070042-11 REVISED**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.

- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VI Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI070042. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

**SECTION IV – AI Special Terms and Conditions – 2R01AI070042-11 REVISED**

REVISED AWARD: This award is revised to correct the budget period start date, consortium term of award, and the Indirect Cost Calculations, per the request from **Christopher Kelly/Dana-Farber Cancer Institute**, dated **3/24/16**.

Supersedes previous Notice of Award dated **02/08/2016**.

\*\*\*\*

This award includes funds awarded for subrecipient activity with **Salk Institute** in the amount of **\$72,849 (\$37,551 direct costs + \$35,298 facilities and administrative costs)**.

This award includes funds awarded for subrecipient activity with **Francis Crick Institute/UK** in the amount of **\$44,301 (\$41,019 direct costs + \$3,282 facilities and administrative costs)**.

Consortiums are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available at [http://grants.nih.gov/grants/policy/nihgps/HTML5/section\\_15/15\\_consortium\\_agreements.htm](http://grants.nih.gov/grants/policy/nihgps/HTML5/section_15/15_consortium_agreements.htm).

\*\*\*\*\*

The budget period anniversary start date for future year(s) will be **April 1**.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Cynthia M. Rodriguez

**Email:** cynthia.rodriguez@nih.gov **Phone:** 240-669-5391 **Fax:** 301-493-0597

**Program Official:** Elizabeth S Church

**Email:** elizabeth.church@nih.gov **Phone:** 240-627-3201

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 2R01AI070042-11 REVISED

**INSTITUTION:** DANA-FARBER CANCER INST

Budget	Year 11	Year 12	Year 13	Year 14	Year 15
Salaries and Wages	\$142,269	\$142,269	\$142,269	\$142,269	\$142,269
Fringe Benefits	\$42,007	\$42,007	\$42,007	\$42,007	\$42,007
Materials & Supplies	\$31,068	\$31,068	\$31,068	\$31,068	\$31,068
Travel	\$3,938	\$3,938	\$3,938	\$3,938	\$3,938
Other	\$18,447	\$18,447	\$18,447	\$18,447	\$18,447
Subawards/Consortium/Contractual Costs	\$117,150	\$117,150	\$117,150	\$117,150	\$117,150
TOTAL FEDERAL DC	\$354,879	\$354,879	\$354,879	\$354,879	\$354,879
TOTAL FEDERAL F&A	\$178,297	\$178,297	\$178,297	\$178,297	\$178,297
TOTAL COST	\$533,176	\$533,176	\$533,176	\$533,176	\$533,176

Facilities and Administrative Costs	Year 11	Year 12	Year 13	Year 14	Year 15
F&A Cost Rate 1	75%	75%	75%	75%	75%

F&A Cost Base 1	\$237,729	\$237,729	\$237,729	\$237,729	\$237,729
F&A Costs 1	\$178,297	\$178,297	\$178,297	\$178,297	\$178,297